Three-Vessel Coronary Artery Disease, Aortic Stenosis, and Constrictive Pericarditis 27 Years after Chest Radiation Therapy: A Case Report

2006 ◽  
Vol 9 (4) ◽  
pp. E728-E730 ◽  
Author(s):  
Raed Aqel ◽  
Steven Lloyd ◽  
Himanshu Gupta ◽  
Gilbert Zoghbi
Keyword(s):  
Coronary Artery Disease ◽  
Radiation Therapy ◽  
Case Report ◽  
Coronary Artery ◽  
Aortic Stenosis ◽  
Constrictive Pericarditis ◽  
Vessel Coronary Artery Disease ◽  
Artery Disease ◽  
Vessel Coronary Artery

scholarly journals Endovascular recanalization of chronic infrarenal aortic occlusion in a patient with two-vessel coronary artery disease: a case report

2021 ◽  
Vol 26 (8) ◽  
pp. 4353
Author(s):  
M. A. Chernyavsky ◽  
Yu. K. Belova ◽  
B. B. Komakha ◽  
N. V. Susanin ◽  
A. G. Vanyurkin ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Case Report ◽  
Coronary Artery ◽  
Perioperative Complications ◽  
Coronary Intervention ◽  
Infrarenal Aorta ◽  
Vessel Coronary Artery Disease ◽  
Endovascular Recanalization ◽  
Artery Disease ◽  
Vessel Coronary Artery

A case report on endovascular treatment of occlusion of the infrarenal aorta and iliac arteries in a patient with hemodynamically significant two-vessel coronary artery disease is presented. After a thorough examination and assessment of surgical risks, a multidisciplinary team meeting chose a staged revascularization strategy: stage 1 — percutaneous coronary intervention in the left anterior descending artery and right coronary artery; stage 2 — endovascular recanalization of aorto-iliac segment occlusion using the kissing stents technique. There were no perioperative complications and the patient was discharged on the 4th day after surgery in a satisfactory condition. The choice in favor of these types of reconstruction and staged revascularization strategy was substantiated. A conclusion was made about the effectiveness and safety of implemented measures.

scholarly journals Cost-effectiveness analysis of percutaneous coronary intervention for single-vessel coronary artery disease: an economic evaluation of the ORBITA trial

BMJ Open ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. e044054
Author(s):  
Victoria McCreanor ◽  
Alexandra Nowbar ◽  
Christopher Rajkumar ◽  
Adrian G Barnett ◽  
Darrel Francis ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Cost Effectiveness ◽  
Coronary Artery ◽  
Coronary Intervention ◽  
Single Vessel ◽  
Vessel Coronary Artery Disease ◽  
Effectiveness Analysis ◽  
Percutaneous Coronary ◽  
Artery Disease ◽  
Vessel Coronary Artery

ObjectiveTo evaluate the cost-effectiveness of percutaneous coronary intervention (PCI) compared with placebo in patients with single-vessel coronary artery disease and angina despite anti-anginal therapy.DesignA cost-effectiveness analysis comparing PCI with placebo. A Markov model was used to measure incremental cost-effectiveness, in cost per quality-adjusted life-years (QALYs) gained, over 12 months. Health utility weights were estimated using responses to the EuroQol 5-level questionnaire, from the Objective Randomised Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina trial and UK preference weights. Costs of procedures and follow-up consultations were derived from Healthcare Resource Group reference costs and drug costs from the National Health Service (NHS) drug tariff. Probabilistic sensitivity analysis was undertaken to test the robustness of results to parameter uncertainty. Scenario analyses were performed to test the effect on results of reduced pharmaceutical costs in patients undergoing PCI, and the effect of patients crossing over from placebo to PCI due to refractory angina within 12 months.SettingFive UK NHS hospitals.Participants200 adult patients with stable angina and angiographically severe single-vessel coronary artery disease on anti-anginal therapy.InterventionsAt recruitment, patients received 6 weeks of optimisation of medical therapy for angina after which they were randomised to PCI or a placebo procedure.Outcome measuresIncremental cost-effectiveness ratio (ICER) expressed as cost (in £) per QALY gained for PCI compared with placebo.ResultsThe estimated ICER is £90 218/QALY gained when using PCI compared with placebo in patients receiving medical treatment for angina due to single-vessel coronary artery disease. Results were robust under sensitivity analyses.ConclusionsThe ICER for PCI compared with placebo, in patients with single-vessel coronary artery disease and angina on anti-anginal medication, exceeds the threshold of £30 000 used by the National Institute of Health and Care Excellence when undertaking health technology assessment for the NHS context.Trial registration: The ORBITA study is registered with ClinicalTrials.gov, number NCT02062593.

scholarly journals Outcome in one-vessel coronary artery disease.

Circulation ◽  
1983 ◽  
Vol 67 (2) ◽  
pp. 283-290 ◽  
Author(s):  
R M Califf ◽  
Y Tomabechi ◽  
K L Lee ◽  
H Phillips ◽  
D B Pryor ◽  
...  
Keyword(s):  
Coronary Artery Disease ◽  
Coronary Artery ◽  
Vessel Coronary Artery Disease ◽  
Artery Disease ◽  
Vessel Coronary Artery
Sign in / Sign up

Export Citation Format

Share Document